Kymera Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Atlas Venture Fund X, L.P. and related entities have reported a change in their beneficial ownership of Kymera Therapeutics, Inc. common stock, now holding 3.4% collectively.
NASDAQ
Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 4.8% of Kymera Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a significant beneficial ownership stake of 14.3% in Kymera Therapeutics Inc. as of March 31, 2026.
NASDAQ
The Vanguard Group reported a 0% beneficial ownership in Kymera Therapeutics Inc. following an internal realignment, with subsidiaries now reporting separately.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership in Kymera Therapeutics, Inc. common stock.
NASDAQ
FMR LLC and its affiliates, including Abigail P. Johnson, reported a beneficial ownership of 11.2% in Kymera Therapeutics Inc. common stock as of December 31, 2025.
NASDAQ
T. Rowe Price Associates, Inc. has reported an increased beneficial ownership of 7.1% in Kymera Therapeutics Inc. common stock.
NASDAQ
FMR LLC and Abigail P. Johnson have disclosed an 8.2% beneficial ownership stake in Kymera Therapeutics Inc. common stock.
NASDAQ
Wellington Management Group and its affiliates report a 7.66% beneficial ownership stake in Kymera Therapeutics, Inc. common stock.
NASDAQ
BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing a 5.4% passive beneficial ownership stake in Kymera Therapeutics, Inc. as of June 30, 2025.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.2% in Kymera Therapeutics, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain 6.8% Passive Stake in Kymera Therapeutics Inc.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a continued 6.8% passive beneficial ownership stake in Kymera Therapeutics Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Vanguard Group Discloses 8.05% Stake in Kymera Therapeutics Inc.
The Vanguard Group has filed an amended Schedule 13G, reporting an 8.05% beneficial ownership stake in Kymera Therapeutics Inc. as of March 31, 2025.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.19% in Kymera Therapeutics, Inc. as of December 31, 2024.